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Polymyositis (PM) and dermatomyositis (DM) are inflammatory muscular diseases of unknown cause. An immune mechanism may cause these inflammatory myopathies.'2 The mainstay of therapy in inflammatory myopathies is corticosteroids. 3 In patients who are resistant to corticosteroids, many therapies are available: immunosuppressive drugs, plasmapheresis, or total body irradiation. 4 These therapies are not always effective and may be responsible for certain serious side effects.
Immunomodulatory therapy with intravenous immunoglobulins (IVIg) has been shown to be useful in a number of diseases featuring disordered immunoregulation. 5 Consequently, we first administered IVIg to patients with chronic refractory inflammatory myopathies in an uncontrolled trial6 7 with favourable results. We describe our experience of IVIg in PM/DM. Service Biochemical assessment was performed by measuring serum levels of the muscle enzymes, creatine kinase (CK) and aldolase, before each IVIg infusion. All the samples were obtained at the same laboratory using constant techniques (normal CK values < 1 10 U/1). Biochemical results were considered "good" (or "moderate improvement") if CK levels dropped between 30 and 50 per cent and "very good" (or "major improvement") over 50 per cent. Below 30 per cent, the therapy was considered as biologically ineffective.
STATISTICAL METHODS
Mean muscle strength assessment for the 35 patients before and after IVIg therapy, was examined using the Student's t test. The mean CK values obtained after each IVIg infusion, and the mean steroid dose reduction before and after IVIg therapy were compared using paired Student's t tests. Significance was assessed at p = 0.05.
Results

CLINICAL ANALYSIS
No patient discontinued therapy because of side effects. A worsening of clinical status was observed in one patient. An absence of clinical improvement was noted in 10 patients despite three or four IVIg infusions. Clinical improvement was observed in 24 patients (70%), with a gain on the initial muscular testing of 18 points for 11 patients, 26 points for six and 36 points or greater for the last seven patients. The mean clinical assessment as gauged by the muscle power score before therapy and after three IVIg infusions showed a statistically significant improvement [mean (SD) initial muscle power for the 35 patients: 46-5 (11 5) points, mean (SD) muscle power after IVIg therapy for the 35 patients: 67 1 2) . The recorded improvement reached a maximum at the fourth perfusion and remained stable afterwards.
In our patients, general tolerance was excellent in 29 subjects. Minor side effects were observed in six others (headaches, fever, shivering and sweating). These adverse reactions disappeared spontaneously after infusion discontinuation and did not re-occur during further IVIg infusions.
Discussion
Although the aetiology of inflammatory myopathies has not been identified, there is considerable evidence that both cellular and humoral autoimmune mechanisms play an important role in their pathogenesis with a difference between polymyositis and dermatomyositis.'0 In childhood dermatomyositis, the necrotic areas and the inflammatory infiltrates have a perivascular distribution. The low success rate obtained with IVIg as first choice treatment of recent PM/DM compared with their benefit when used in association with steroids in chronic refractory PM/DM suggests a synergistic action of these two drugs in inflammatory myopathies. Steroids have a mainly cellular immune action, inhibiting the production of interleukin-2 and gamma interferon of CD4 cells and of cytokines from macrophages, but also reducing the humoral response when used in high doses. Steroids have a possible complementary action with IVIg, necessitating their combined use for maximum effect.
To appreciate the real place of IVIg in the treatment of inflammatory myopathies, we have recently initiated an international randomised study. It is a multicentre prospective open trial, comparing the effectiveness of IVIg versus immunosuppressive agents in adults suffering from active PM or DM resistant to steroids. The main assessment, based on the clinical improvement of the proximal muscle weakness, consists of a functional muscular scale, muscular strength testing, and muscle enzyme levels. The criterion of eligibility for the trial is a MRC modified score below 72. We retained a stringent criterion for defining improvement, that is, above 18 grades. A stratification between PM and DM has been used.
